Uniform Controlled Substances Law; include certain hemp products on Schedule I.
SB 2314 amends Mississippi’s Schedule I controlled substances list in Section 41-29-113 to add a new category covering any product derived from the hemp plant that is designed for human ingestion or consumption and is not approved by the U.S. Food and Drug Administration. The bill also clarifies the existing marijuana/hemp language so that hemp regulated under Mississippi’s hemp statutes remains exempt, but non-FDA-approved consumable hemp products are treated as Schedule I substances. The measure is paired with the state’s existing Schedule I framework, which already lists numerous opiates, hallucinogens, depressants, stimulants, synthetic cannabinoids, and related analogues.
In practical terms, the bill would make the manufacture, possession, sale, or distribution of unapproved consumable hemp products subject to Mississippi’s most restrictive controlled-substances penalties, unless another exemption applies. It preserves an exemption for FDA-approved hemp-derived products and for cannabidiol in approved legend drug products or products obtained under existing law. The act is set to take effect on July 1, 2025.
The overall sentiment in the available record appears strongly supportive in the Senate, where the bill passed 51-0 on February 6, 2025. No committee transcript is available, so there is no recorded floor or committee debate to indicate organized opposition in the provided materials. The unanimous vote suggests broad agreement among senators on the need to tighten regulation of consumable hemp products.
The main point of contention implied by the bill’s text is the treatment of hemp-derived products that are sold for ingestion but are not FDA-approved. Supporters appear to view these products as needing to be controlled alongside other Schedule I substances, while the carve-outs for regulated hemp and FDA-approved products indicate an effort to avoid disrupting lawful industrial hemp and approved medical or consumer products. The bill’s language may be significant for hemp retailers, manufacturers, distributors, consumers of hemp edibles and beverages, and law enforcement tasked with distinguishing lawful hemp from prohibited consumable hemp products.
The bill amends Mississippi Code Section 41-29-113, the state’s Schedule I controlled substances statute, by expressly including non-FDA-approved hemp-derived products intended for human ingestion or consumption. It narrows the practical scope of Mississippi’s hemp exemption by excluding these consumable products from the protections otherwise available to hemp under Sections 69-25-201 through 69-25-221, while preserving exemptions for FDA-approved hemp-derived products and certain cannabidiol products authorized under existing law. This change affects hemp processors, retailers, distributors, consumers, and enforcement agencies by subjecting a new class of consumable hemp items to Schedule I treatment and associated criminal penalties.
The available voting history shows strong support: the Mississippi Senate passed SB 2314 unanimously, 51-0, on February 6, 2025. With no committee transcript provided, there is no recorded public debate in the supplied materials, but the vote suggests little visible legislative resistance in the Senate. The bill’s framing indicates a policy preference for tighter control over intoxicating or unapproved hemp consumables.
The central issue is whether hemp-derived products designed for ingestion should remain outside controlled-substance law when they are not FDA-approved. Supporters of the bill appear concerned about unregulated consumable hemp products and their potential psychoactive or public-safety effects, while the bill’s exemptions show an intent to preserve lawful hemp commerce, industrial hemp uses, and FDA-approved products. The likely affected stakeholders include hemp businesses, consumers of hemp edibles and beverages, and law enforcement, though no direct opposition is documented in the provided record.